Governor Andrew M. Cuomo today announced an agreement between New York State and GW Pharmaceuticals to develop clinical trials using an active ingredient derived from the marijuana plant to help treat children diagnosed with epilepsy who suffer from seizures and other medical complications. The children who will participate in these trials are those whose medical conditions have not been successfully treated by other methods, and New York will be the second state in the nation to initiate trials for the extract, known as cannabidiol (CBD).

Dr. Geoffrey Guy, Chairman of GW Pharmaceuticals, said, “We are pleased to be partnering with the State of New York in this groundbreaking program designed to establish a scientific foundation that expands the understanding of how CBD works in children with treatment-resistant epilepsies. This collaboration with the State of New York builds on the foundation established by our relationship with New York University’s Langone Medical Center where 60 children are already authorized by the FDA to receive Epidiolex.”